tag:blogger.com,1999:blog-36634196.post3514577601549018226..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: The Blockbuster Model is Dead, Sort OfChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-36634196.post-949480734222440992008-02-14T10:22:00.000-05:002008-02-14T10:22:00.000-05:00Cheaper? No -- I'm saying (or more accurately IMS ...Cheaper? No -- I'm saying (or more accurately IMS is saying, and I agree) that the real growth in the pharma market is coming from specialty care products, not the big primary care blockbusters of the past.Kate Rawsonhttps://www.blogger.com/profile/03157832353070771521noreply@blogger.comtag:blogger.com,1999:blog-36634196.post-5264993395433324512008-02-14T09:51:00.000-05:002008-02-14T09:51:00.000-05:00Are you saying it is cheaper to develop an non-blo...Are you saying it is cheaper to develop an non-block buster than it is to develop a blockbuster?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-21603853465697162582008-02-12T12:54:00.000-05:002008-02-12T12:54:00.000-05:00The running theme amongst our team of amateur grad...The running theme amongst our team of amateur graduate students is that panacea therapeutics capable of being administered by primary care physicians are going to become necessarily more difficult to develop, at least until the diagnostic technology catches up. We feel that this is simply because the science of understanding disease is not only too vast for individual MDs, but in many cases for PhDs outside their specialized field. <BR/>Well its probably wishful thinking, but we like to prognosticate that in the future the current surplus of PhDs will find a place in the industry as technocrat liaisons between healthcare providers and therapeutic engineers.Anonymousnoreply@blogger.com